Cancer drug dose optimization draws calls for trials after FDA approval
Patients and researchers want trials of lower, less frequent or shorter cancer treatment, but evidence has not established a universal alternative.
By Tom Brennan · Health & Medicine Correspondent
3 min read
Cancer drug dose optimization is drawing new calls from patients, doctors and researchers for studies after medicines reach the market. The question matters because lower amounts, wider spacing between treatments or shorter courses might reduce side effects and costs, yet evidence has not shown that any one reduced regimen works for every cancer or patient, according to KFF Health News.
The debate centers in part on immunotherapies nivolumab, sold as Opdivo, and pembrolizumab, sold as Keytruda. It is not a guide for patients to alter treatment on their own: Merck said changes in dose or duration that have not been tested in comparable clinical trials could weaken a treatment's effect.
What does cancer drug dose optimization mean?
Dose optimization can mean three different things: using less medicine at each administration, giving doses farther apart, or stopping treatment after a shorter total period. Each approach needs evidence of its own, since a result for one schedule or cancer type does not establish that another will work as well.
KFF Health News reported that clinicians in Canada, Israel, Sweden and other countries have used lower doses, longer intervals or shorter courses of nivolumab and pembrolizumab than U.S. FDA recommendations. The report also described Indian research in which nivolumab doses as low as one-twelfth of the labeled amount had effects in several cancers.
That Indian work does not settle whether ultra-low doses match standard immunotherapy. MedPath's summary of the reporting said the studies compared low-dose nivolumab with older chemotherapy rather than with standard nivolumab or pembrolizumab; it attributed to Fox Chase Cancer Center's Jessica Bauman the view that a randomized comparison is needed.
A patient's experience helped focus the debate
Chuck Manski, a Northwestern University economist, received monthly nivolumab infusions for advanced melanoma for six months in 2022, KFF Health News reported. He said the treatment damaged his thyroid, leaving him dependent on medication, and caused severe dryness of his eyes, mouth and lips.
Manski said he had no signs or symptoms of cancer when he chose to stop instead of completing the one-year course described in the FDA protocol. His account has become part of a broader push for research into whether some established regimens expose patients to more treatment than they need.
Why are lower-dose trials uncommon?
KFF Health News reported that dose-optimization research is rare once a drug has cleared its early development and reached the market. The report identified financial incentives affecting drugmakers, hospitals and physicians, while stopping short of saying those incentives determine prescribing decisions.
A study of 29 costly cancer medicines estimated that using minimum necessary doses could have saved the U.S. health system about $31 billion in 2024, KFF Health News reported. Cost also affects access: a recent KFF survey found 43% of U.S. adults had skipped medication in the prior year because of cost, and a 2022 Vanderbilt study found 30% of cancer-drug prescriptions among Medicare enrollees went unfilled.
Merck spokesperson Julie Cunningham said pembrolizumab's recommended dosing rests on extensive testing. The central unresolved issue is whether well-designed trials can identify reduced regimens that preserve benefit for specific cancers and patients.
This story draws on original reporting from Medical Xpress.